UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 23, 2018
HTG Molecular Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-37369 |
|
86-0912294 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|||
|
3430 E. Global Loop Tucson, AZ |
|
85706 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code: (877) 289-2615
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( § 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On February 23, 2018, we and Cantor Fitzgerald & Co. (“Cantor”) mutually agreed to terminate our Controlled Equity Offering SM Sales Agreement (“Sales Agreement”) dated April 13, 2017. In connection with the Sales Agreement, we previously filed a prospectus supplement (File No. 333-216977) with the Securities and Exchange Commission on April 13, 2017, and amendments thereto on June 2, 2017 and January 16, 2018, relating to the offer and sale of our common stock through Cantor, acting as our sales agent. No further sales will be made under the Sales Agreement or the prospectus supplement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date: February 27, 2018 |
|
|
|
HTG Molecular Diagnostics, Inc. |
||
|
|
|
|
|
|||
|
|
|
|
|
By: |
|
/s/ Shaun D. McMeans |
|
|
|
|
|
|
|
Shaun D. McMeans |
|
|
|
|
|
|
|
Senior Vice President and Chief Financial Officer |